• SN-38 Disrupts FUBP1–FUSE Binding: New Mechanism in Cancer T

  2026-05-17

  This study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, not only acts as a DNA topoisomerase I inhibitor but also directly impairs the binding of the oncogenic regulator FUBP1 to its DNA target, FUSE. These findings provide a dual-mechanism perspective for the application of SN-38 in advanced cancer research and suggest new molecular targets for therapeutic intervention.

• Ribonuclease R (20 U/μL): Transforming Circular RNA Enrichme

  2026-05-16

  Ribonuclease R (20 U/μL) from APExBIO redefines circular RNA research by enabling selective linear RNA degradation and robust enrichment of circular RNA species. This guide demystifies experimental workflows, highlights protocol innovations, and delivers troubleshooting insights for advanced RNA structure-function studies.

• Streptavidin – Cy5: Precision Biotin Detection in Tumor Path

  2026-05-15

  Explore how Streptavidin – Cy5 advances biotin detection in cancer research. This article uniquely connects Cy5 fluorescent dye technology to the mechanistic study of apoptosis and breast cancer progression.

• BAPTA Calcium Chelator: Dissecting IP3R/Ca2+ Axis in Cell Ap

  2026-05-15

  Explore how BAPTA, a high-affinity calcium chelator, enables precise dissection of the IP3R/Ca2+/STAT3 signaling axis in apoptosis research. This article uniquely analyzes recent mechanistic findings and offers advanced assay guidance for environmental toxicology and cell signaling studies.

• Ibuprofen in Colon Cancer Research: Protocols & Applied Insi

  2026-05-14

  Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) is advancing beyond its classic NSAID role, emerging as a precision tool for apoptosis induction and cell cycle arrest in colon carcinoma models. This guide delivers optimized experimental workflows, comparative advantages, and troubleshooting strategies to empower robust, reproducible research using APExBIO’s Ibuprofen.

• JNJ-26481585 (Quisinostat): Applied Workflows for HDAC Inhib

  2026-05-14

  JNJ-26481585 (Quisinostat) is redefining cancer research through its potent, selective modulation of epigenetic states, enabling researchers to induce apoptosis, overcome drug resistance, and interrogate tumor suppressor pathways with precision. This guide details advanced experimental workflows, troubleshooting strategies, and real-world applications that maximize reproducibility and biological discovery with this next-generation HDAC inhibitor.

• TSPAN18-STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-05-13

  Zhou et al. (2023) uncover a novel regulatory mechanism in which TSPAN18 stabilizes STIM1 by preventing its ubiquitination by TRIM32, promoting calcium influx and facilitating bone metastasis in prostate cancer. This mechanistic insight highlights new potential targets for therapeutic intervention and advances our understanding of metastatic progression in hormone-responsive cancers.

• CHIR-99021 (CT99021): Precision GSK-3 Inhibition for Persona

  2026-05-13

  Discover how CHIR-99021 (CT99021) enables next-generation stem cell research and personalized assay platforms by precisely modulating key pathways. This article uniquely explores its translational impact for tailored disease modeling and prescreening, offering insight beyond conventional protocols.

• Dextromethorphan Hydrobromide in Neuroprotection: Mechanisms

  2026-05-12

  Explore the unique neuroprotective mechanisms of Dextromethorphan hydrobromide, a potent NMDA receptor antagonist, and discover how recent advances in metabolic modulation can inform experimental design for excitotoxicity and cerebral ischemia research.

• Elevated Lipid Concentration Enhances LNP-Mediated mRNA Expr

  2026-05-12

  This study demonstrates that lipid nanoparticles (LNPs) formulated with higher lipid and nucleic acid concentrations retain optimal physicochemical properties and significantly boost in vivo gene expression. The findings offer practical guidance for improving the scalability and stability of mRNA-LNP therapeutics, particularly in the context of efficient mRNA delivery and bioluminescent reporter assays.

• Resazurin Sodium Salt: Advancing Translational Cell Viabilit

  2026-05-11

  This thought-leadership article explores the mechanistic, experimental, and strategic imperatives of deploying Resazurin sodium salt as a fluorogenic oxidation-reduction indicator in translational research. Drawing on recent breakthroughs in glutamine metabolism and hepatic stellate cell biology, we contextualize assay design and optimization for robust, clinically relevant insights in liver fibrosis and beyond. This guide distinguishes itself with actionable recommendations, critical evidence integration, and a forward-thinking outlook for next-generation cell viability platforms.

• Puromycin Aminonucleoside: Precision Tools for Podocyte Inju

  2026-05-11

  Discover how puromycin aminonucleoside enables advanced podocyte injury models for nephrotic syndrome research. This article uniquely integrates mechanistic insights with practical assay strategies to drive reproducible renal pathology studies.

• Chemically Modified NGF mRNA-LNPs Mitigate Peripheral Neurop

  2026-05-10

  This study demonstrates that lipid nanoparticle (LNP) delivery of chemically modified NGFR100W mRNA enables the in vivo production of a 'painless' nerve growth factor, effectively reducing chemotherapy-induced peripheral neuropathy in mice. The research highlights the flexibility of in vitro transcribed, sequence-optimized mRNA for rapid therapeutic development and functional validation.

• Naftifine HCl: Mechanistic Leverage for Translational Antifu

  2026-05-09

  This thought-leadership article unpacks the mechanistic depth of Naftifine HCl, an allylamine antifungal agent, offering translational researchers both scientific insight and strategic protocol guidance. Drawing parallels from landmark signaling research in muscle progenitor biology, we contextualize Naftifine’s squalene 2,3-epoxidase inhibition within advanced antifungal workflows, highlight assay optimization, and outline a visionary path for next-generation mycology research. Distinct from product pages, this piece integrates original literature, comparative analysis, and practical workflow recommendations.

• Optimizing Sulfaphenazole Derivatives: Antitubercular Activi

  2026-05-09

  This study systematically optimized sulfaphenazole-based sulfonamides to enhance anti-Mycobacterium tuberculosis activity while minimizing cytochrome P450 2C9 inhibition. Key derivatives retained potent antibacterial effects with reduced risk of drug-drug interactions, offering new avenues for tuberculosis therapy design.

453 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page